← Leaderboards
Marielle Yohe
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsClinical TrialsRhabdomyosarcomaMutationCollaborationsMalignant Childhood NeoplasmPathway InteractionsSignal TransductionMeksMutateGenesTargeted AgentMap Kinase GeneXenograft ModelNeuroblastomaCell LineGenomicsInhibitor/AntagonistPhosphorylationPlexiform NeurofibromaMalignant NeoplasmsNeurofibromatosis 1Childhood
Grant awards (36)
Advancing RAS and RASopathy Therapies$849,996
ZIA · FY2025 · CA · contact PI
Improving Pediatric Melanoma Outcomes in a Longitudinally Evaluated Cohort$607,140
ZIA · FY2025 · CA · contact PI
Targeting RAS in Pediatric Cancer$607,140
ZIA · FY2025 · CA · contact PI
The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle Differentiation$242,856
ZIA · FY2025 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$121,429
ZIA · FY2025 · CA · contact PI
Advancing RAS and RASopathy Therapies$646,143
ZIA · FY2024 · CA · contact PI
Targeting RAS in Pediatric Cancer$646,143
ZIA · FY2024 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancers$516,915
ZIA · FY2024 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$387,686
ZIA · FY2024 · CA · contact PI
The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle Differentiation$258,457
ZIA · FY2024 · CA · contact PI
Improving Pediatric Melanoma Outcomes in a Longitudinally Evaluated Cohort$129,229
ZIA · FY2024 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancers$577,904
ZIA · FY2023 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$407,933
ZIA · FY2023 · CA · contact PI
Advancing RAS and RASopathy Therapies$254,957
ZIA · FY2023 · CA · contact PI
Targeting RAS in Pediatric Cancer$237,960
ZIA · FY2023 · CA · contact PI
The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle Differentiation$220,963
ZIA · FY2023 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancers$829,718
ZIA · FY2022 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$414,858
ZIA · FY2022 · CA · contact PI
Targeting RAS in Pediatric Cancer$255,297
ZIA · FY2022 · CA · contact PI
Advancing RAS and RASopathy Therapies$95,737
ZIA · FY2022 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancers$741,111
ZIA · FY2021 · CA · contact PI
Targeting RAS in Pediatric Cancer$222,334
ZIA · FY2021 · CA · contact PI
Defining the Mechanism of Action of Rigosertib in Pediatric Cancers$222,334
ZIA · FY2021 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$148,222
ZIA · FY2021 · CA · contact PI
Advancing RAS and RASopathy Therapies$148,222
ZIA · FY2021 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancers$504,049
ZIA · FY2020 · CA · contact PI
Targeting RAS in Pediatric Cancer$151,215
ZIA · FY2020 · CA · contact PI
Defining the Mechanism of Action of Rigosertib in Pediatric Cancers$151,215
ZIA · FY2020 · CA · contact PI
Regulation of differentiation and invasion in RMS by ASAP1$100,810
ZIA · FY2020 · CA · contact PI
Advancing RAS and RASopathy Therapies$100,810
ZIA · FY2020 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits RMS cell growth$495,197
ZIA · FY2019 · CA · contact PI
Defining the Mechanism of Action of Rigosertib in Pediatric Cancers$247,599
ZIA · FY2019 · CA · contact PI
Targeting RAS in Pediatric Cancer$148,559
ZIA · FY2019 · CA · contact PI
Advancing RAS and RASopathy Therapies$99,040
ZIA · FY2019 · CA · contact PI
Defining the Mechanism of Action of Rigosertib in Pediatric Cancers$332,085
ZIA · FY2018 · CA · contact PI
Dual Blockade of IGF1R and MEK synergistically inhibits RMS cell growth$332,085
ZIA · FY2018 · CA · contact PI